Keyphrases
Prostate Cancer
56%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
41%
Androgen Deprivation Therapy
38%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
36%
Overall Survival
28%
Phase II Trial
27%
Docetaxel
27%
Prostate-specific Antigen
22%
Southwest Oncology Group
22%
Advanced Prostate Cancer
19%
Chemotherapy
16%
Hormone-sensitive Prostate Cancer
16%
Castration-resistant Prostate Cancer
15%
Enzalutamide
13%
Confidence Interval
10%
Clinical Trials
10%
Prostate-specific Antigen Level
10%
Paclitaxel
10%
Phase II Study
10%
Placebo
10%
Estramustine
9%
Prostate Cancer Patients
9%
Hazard Ratio
9%
Prednisone
9%
Olaparib
9%
Cancer Clinical Trials
9%
Randomized Phase II Trial
8%
Group Studies
8%
Cisplatin
7%
Metastatic Disease
7%
Patient Management
7%
Progression-free Survival
7%
Hormonal Therapy
7%
Mitoxantrone
7%
Consensus Conference
7%
Bladder Cancer
6%
PARP Inhibitor (PARPi)
6%
Prostate Cancer Cells
6%
Patients with Prostate Cancer
6%
Newly Diagnosed
6%
Prostate Radiotherapy
6%
Prostate-specific Antigen Response
6%
Quality of Life
6%
Adverse Events
5%
5-fluorouracil (5-FU)
5%
Tumor
5%
Hormone Refractory
5%
Gemcitabine
5%
Androgen Receptor
5%
Disease Progression
5%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Castration Resistant Prostate Cancer
46%
Androgen
41%
Prostate Specific Antigen
33%
Disease
32%
Overall Survival
28%
Docetaxel
28%
Chemotherapy
21%
Clinical Trial
20%
Malignant Neoplasm
17%
Neoplasm
15%
Paclitaxel
14%
Progression Free Survival
13%
Phase II Trials
13%
Enzalutamide
13%
Placebo
10%
Biological Marker
10%
Transitional Cell Carcinoma
10%
Cisplatin
9%
Olaparib
9%
Estramustine
9%
Bladder Cancer
8%
Metastasis
7%
Prednisone
7%
Androgen Receptor
7%
Adverse Event
6%
Hormone Cancer Therapy
6%
Group Trial
6%
Fluorouracil
6%
Gemcitabine
6%
Carboplatin
5%
Etoposide
5%
Mitoxantrone
5%
Disease Exacerbation
5%
Abiraterone
5%
Medicine and Dentistry
Prostate Cancer
86%
Diseases
25%
Castration Resistant Prostate Cancer
23%
Oncology
22%
Androgen
20%
Prostate Specific Antigen
18%
Chemotherapy
16%
Overall Survival
16%
Androgen Deprivation Therapy
16%
Clinical Trial
13%
Malignant Neoplasm
10%
Transitional Cell Carcinoma
10%
Metastatic Carcinoma
9%
Paclitaxel
9%
Docetaxel
8%
Progression Free Survival
8%
Neoplasm
8%
Olaparib
8%
Bladder Cancer
7%
Hormone Therapy
6%
Biological Marker
6%
Arm
6%
Phase II Trials
6%
Cisplatin
6%
Group Trial
5%
Urothelial Cancer
5%
Androgen Receptor
5%
Homologous Recombination
5%
Recombination Repair
5%
Hazard Ratio
5%